Allergan Inc (AGN)
10 Mar 2014
|Market Cap (Mil.):||$38,200.88|
|Shares Outstanding (Mil.):||298.47|
SAN FRANCISCO - A Texas judge has upheld U.S. patents covering Allergan Inc's Lumigan glaucoma drug through 2027, the company said in a regulatory filing on Tuesday, helping to send its shares up 6 percent.
SAN FRANCISCO Jan 14 - A Texas judge has upheld U.S. patents covering Allergan Inc's Lumigan glaucoma drug through 2027, the company said in a regulatory filing on Tuesday, helping to send its shares up 6 percent.
|Astellas Pharma Inc (4503.T)||¥6,438||-67.00|
|SANTEN PHARMACEUTICAL CO., LTD. (4536.T)||¥4,770||+45.00|
|Lupin Limited (LUPN.NS)||Rs958.25||-8.05|
|Nestle SA (NESN.VX)||CHF66.10||-0.30|
|Johnson & Johnson (JNJ.N)||$93.17||-0.15|
|Pfizer Inc. (PFE.N)||$32.31||-0.12|
|Novartis AG (NOVN.VX)||CHF72.50||-0.35|
|High Tech Pharm Co.,Ltd. (106190.KQ)||₩14,350.00||-100.00|
|Merck & Co., Inc. (MRK.N)||$57.06||-0.41|
|Roche Holding Ltd. (ROG.VX)||CHF258.60||-0.30|
Earnings vs. Estimates
Analyst Research Reports
Provider: Wright Reports
Trading Report for (AGN). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: S&P Capital IQ – STARS Reports
Provider: Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.